Table 2.
Characteristics of the 95 studies that met inclusion criteria
| Reports included | 95 |
| Countries and territories included | 57 |
| Year range during which data were collected | 1952-2010 |
| Total pediatric patients with drug-susceptibility testing (DST) results for at least isoniazid and rifampicin | 8351 |
| New (%) | 2980 (36) |
| Previously treated (%) | 226 (3) |
| Unknown/unspecified treatment history (%) | 5145 (62) |
| Number of reports (%) | Number of pediatric patients (%) | |
|---|---|---|
| Number of pediatric patients with DST results per report | ||
| 0-10 | 28 (29) | 114 (1) |
| 11-50 | 35 (37) | 749 (9) |
| 51-100 | 14 (15) | 1128 (14) |
| 101-500 | 15 (16) | 2802 (34) |
| >500 (max. 2,456) | 3 (3) | 3558 (43) |
| Source of data used in report | ||
| Reported surveillance data | 20 (21) | 3908 (47) |
| Hospital records | 48 (51) | 2736 (33) |
| Laboratory records | 9 (9) | 802 (10) |
| Representative population sample | 9 (9) | 270 (3) |
| Other or not specified | 4 (4) | 542 (6) |
| Reports with restricted study populations* | 32 (34) | 720 (9) |
*
Includes study populations restricted to patients with pulmonary TB, smear positive TB, extrapulmonary TB, TB meningitis, TB pleurisy, or HIV coinfection; patients with no previous treatment, patients who failed treatment, or patients on DOTS treatment; patients with HIV-infected family member(s); refugees; and/or contacts of source cases with DST results.